Curative Biotechnology Inc. Files S-1 Registration Statement

TL;DR

<b>Curative Biotechnology Inc. has filed an S-1 registration statement with the SEC.</b>

AI Summary

Curative Biotechnology Inc (CUBT) filed a IPO Registration (S-1) with the SEC on May 6, 2024. Curative Biotechnology Inc. filed an S-1 registration statement with the SEC on May 6, 2024. The company was formerly known as Connectyx Technologies Corp, with a name change on May 22, 2007. The filing pertains to the Securities Act of 1933. Curative Biotechnology Inc. is incorporated in Florida (FL). The company's SIC code is 2836 for Biological Products (No Diagnostic Substances).

Why It Matters

For investors and stakeholders tracking Curative Biotechnology Inc, this filing contains several important signals. This S-1 filing indicates the company is preparing for a significant corporate event, potentially an offering or restructuring, which could impact its capital structure and shareholder value. The historical information about former names and incorporation details provides context for the company's evolution and potential strategic shifts.

Risk Assessment

Risk Level: low — Curative Biotechnology Inc shows low risk based on this filing. The filing is an S-1 registration statement, which is a preliminary step and does not contain specific financial performance data or operational updates that would indicate immediate risk.

Analyst Insight

Monitor for subsequent filings related to this S-1 to understand the company's strategic direction and potential capital raising activities.

Key Numbers

• 20240506 — Filing Date (S-1 Registration Statement)
• 20070522 — Name Change Date (From Connectyx Technologies Corp)
• 333-279159 — SEC File Number (S-1 Filing)

Key Players & Entities

• Curative Biotechnology Inc. (company) — Filer
• SEC (regulator) — Filing authority
• Connectyx Technologies Corp (company) — Former company name
• Securities Act of 1933 (regulatory) — Act under which filing is made
• Florida (location) — State of incorporation

FAQ

Industry Context

Curative Biotechnology Inc. operates in the biotechnology sector, focusing on biological products.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities.

What Investors Should Do

1. Review the full S-1 filing for detailed information on the company's business, financials, and proposed use of proceeds.
2. Track future SEC filings from Curative Biotechnology Inc. for updates on their corporate activities.
3. Research the biotechnology industry for comparable companies and market trends.

Key Dates

• 2024-05-06: S-1 Filing — Registration statement filed with the SEC.

Year-Over-Year Comparison

This is a new S-1 filing, so no prior filing data is available for comparison.

Key Financial Figures

• $0.0001 — lic offering of shares of common stock, $0.0001 par value per share ("Common Stock"), o
• $4.00 — poration, at a public offering price of $4.00 per share based on a reverse stock spli
• $0.0269 — mon Stock as quoted on the OTC Pink was $0.0269 per share, or $10.76 on a post reverse
• $10.76 — the OTC Pink was $0.0269 per share, or $10.76 on a post reverse split basis. Manage
• $5.8 million — d assuming the receipt of approximately $5.8 million in net proceeds from this offering, we

Filing Documents

• forms-1.htm (S-1) — 2480KB
• ex3-3.htm (EX-3.3) — 7KB
• ex10-31.htm (EX-10.31) — 110KB
• ex10-32.htm (EX-10.32) — 100KB
• ex10-33.htm (EX-10.33) — 76KB
• ex10-34.htm (EX-10.34) — 9KB
• ex10-35.htm (EX-10.35) — 9KB
• ex10-36.htm (EX-10.36) — 12KB
• ex10-37.htm (EX-10.37) — 10KB
• ex10-38.htm (EX-10.38) — 16KB
• ex10-39.htm (EX-10.39) — 16KB
• ex10-40.htm (EX-10.40) — 16KB
• ex10-41.htm (EX-10.41) — 10KB
• ex10-42.htm (EX-10.42) — 16KB
• ex10-43.htm (EX-10.43) — 13KB
• ex10-44.htm (EX-10.44) — 12KB
• ex10-45.htm (EX-10.45) — 12KB
• ex10-46.htm (EX-10.46) — 14KB
• ex10-47.htm (EX-10.47) — 2KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 60KB
• forms-1_001.jpg (GRAPHIC) — 3KB
• forms-1_002.jpg (GRAPHIC) — 2KB
• forms-1_003.jpg (GRAPHIC) — 1KB
• forms-1_005.jpg (GRAPHIC) — 31KB
• forms-1_004.jpg (GRAPHIC) — 4KB
• ex3-3_001.jpg (GRAPHIC) — 234KB
• ex3-3_002.jpg (GRAPHIC) — 160KB
• ex3-3_003.jpg (GRAPHIC) — 190KB
• ex3-3_004.jpg (GRAPHIC) — 158KB
• ex3-3_005.jpg (GRAPHIC) — 137KB
• ex3-3_006.jpg (GRAPHIC) — 164KB
• ex3-3_007.jpg (GRAPHIC) — 157KB
• ex10-47_001.jpg (GRAPHIC) — 416KB
• ex10-47_002.jpg (GRAPHIC) — 118KB
• 0001493152-24-017952.txt (&nbsp;) — 10852KB
• cubt-20231231.xsd (EX-101.SCH) — 56KB
• cubt-20231231_cal.xml (EX-101.CAL) — 62KB
• cubt-20231231_def.xml (EX-101.DEF) — 253KB
• cubt-20231231_lab.xml (EX-101.LAB) — 414KB
• cubt-20231231_pre.xml (EX-101.PRE) — 348KB
• forms-1_htm.xml (XML) — 825KB

DILUTION

DILUTION 36 DETERMINATION OF OFFERING PRICE 38 DIVIDEND POLICY 38 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 39

BUSINESS

BUSINESS 45 SELLING STOCKHOLDERS 67

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 70 MANAGEMENT 77

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 82 PRINCIPAL STOCKHOLDERS 87 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 89

UNDERWRITING

UNDERWRITING 91 LEGAL MATTERS 96 EXPERTS 96 WHERE YOU CAN FIND MORE INFORMATION 96 INDEX TO FINANCIAL STATEMENTS F-1 You should rely only on information contained in this prospectus. We have not, and the Underwriter has not, authorized anyone to provide you with additional information or information different from that contained in this prospectus. Neither the delivery of this prospectus nor the sale of our securities means that the information contained in this prospectus is correct after the date of this prospectus. This prospectus is not an offer to sell or the solicitation of an offer to buy our securities in any circumstances under which the offer or solicitation is unlawful or in any state or other jurisdiction where the offer is not permitted. The information in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. No person is authorized in connection with this prospectus to give any information or to make any representations about us, the securities offered hereby or any matter discussed in this prospectus, other than the information and representations contained in this prospectus. If any other information or representation is given or made, such information or representation may not be relied upon as having been authorized by us. For investors outside the United States: we have not, the Selling Stockholders has not, and the Underwriter has not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities offered hereby and the distribution of this prospectus outside of the United States. Until ,

View Full Filing

View this S-1 filing on SEC EDGAR